Interesting ABT Put And Call Options For August 2026

Stock Options Channel highlights option strategies on Abbott Laboratories (ABT: $127.36): a $90 put (bid $0.50) would set an effective purchase basis of $89.50, sits ~29% below the current price, and is modeled to expire worthless with 91% odds, yielding 0.56% (0.82% annualized) if so. On the call side, selling a $130 covered call (bid $7.20) against shares purchased at $127.36 would produce a 7.73% total return if called at the August 2026 expiry; the $130 strike is ~2% out‑of‑the‑money with a 48% probability of expiring worthless and a 5.65% (8.39% annualized) YieldBoost. Implied volatilities are 36% for the put and 23% for the call versus a 22% trailing 12‑month volatility.

Analysis

Market structure: The option chain shows asymmetric pricing — deep OTM $90 puts imply IV ~36% versus $130 calls at 23% while realized TTM vol is 22% — a classic downside skew that benefits liquidity providers and volatility sellers collecting small, steady premiums. Demand for downside protection (puts) raises put IV despite tiny absolute premiums, signaling investor willingness to pay for crash insurance while yield-seeking investors supply call/put premium. Cross-asset: a risk-off shock that lifts put demand would likely compress equities, send Treasuries lower (higher prices) and strengthen USD; option gamma flows could amplify intraday moves in ABT and peers.

Risk assessment: Tail risks are regulatory/FDA actions, device recalls, or a large litigation settlement — each could knock 20-40% off ABT in weeks. Near term (days–weeks) option IVs can gap; short-term catalysts include earnings, FDA decisions, or macro growth data; long term (quarters) fundamentals and cash returns matter. Hidden dependencies: corporate buybacks, pension flows, and hospital capex cycles can swing demand for devices; vol-of-vol and skew can change rapidly around idiosyncratic news.

Trade implications: If comfortable owning ABT, the Aug 2026 $130 covered-call yields ~7.7% total to call date vs tiny 0.56% for cash‑secured $90 puts — prefer covered calls for risk-adjusted income. Tactical plays: sell medium-dated covered calls or 3–6 month put spreads to harvest 3–8% per trade; buy modest call spreads if you want upside exposure given relatively cheap call IV (~23%). Rotate modestly into healthcare (ABT) vs cyclicals if macro growth decelerates.

Contrarian angles: Consensus income-sellers may be underpricing assignment risk and overestimating call expiry odds; the 91% put-expiry metric understates jump risk from regulatory events. The market is likely underweight long-call exposure (cheap calls) and overweights cheap deep-OTM put-selling; a small-sized long-call-spread or synthetic long funded by selling calendar puts could outperform if volatility reprices. Historically, healthcare skew tightens after idiosyncratic shocks, offering roll opportunities.

Key Decisions for Investors

• Establish a 2–3% portfolio long position in ABT at current levels (~$127), simultaneously sell Aug 2026 $130 covered calls (collect ~$7.20) to lock a 7–8% total return to expiry; cut position if ABT closes below $115 on a weekly basis or if IV for $130 calls rises >30% (re-evaluate/roll).
• Do NOT sell cash‑secured $90 puts as a primary yield trade (0.56% payoff is poor capital efficiency); instead, sell 60–90 day put spreads (e.g., sell 1x 105/95 put spread or similar 8–12% OTM structure) targeting 2–4% premium per trade and max assigned price ≤ current price -10%.
• Buy limited-risk bullish call spreads as a leverage play: deploy 0.5–1.0% portfolio capital to buy Aug 2026 $130/$150 call spreads (or nearer-dated 9–12 month equivalent) to capture upside if company-specific catalysts (FDA/earnings/M&A) materialize, cap loss at spent premium.
• Express relative conviction with a small pair trade: go 1% long ABT vs 0.8% short MDT (or IHI) for 3–12 month horizon to capture potential ABT defensive/outperformance; exit if spread reverses by 6% or on ABT regulatory headline.